Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody designed to selectively target the TNF-like weak inducer of apoptosis receptor (TWEAK receptor, TweakR). This receptor is naturally engaged by its ligand TWEAK (TNFRSF12A), which activates various cellular responses. By binding to TweakR, Enavatuzumab inhibits tumor proliferation through direct receptor signaling and promotes antibody-dependent cell-mediated cytotoxicity (ADCC). This antibody has demonstrated efficacy in recruiting and activating myeloid effector cells to eradicate tumor cells. Enavatuzumab has shown to inhibit the growth of a range of human TweakR-positive cancer cell lines and xenografts both in vitro and in vivo, marking it as a potent therapeutic agent in cancer research and treatment.
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody designed to selectively target the TNF-like weak inducer of apoptosis receptor (TWEAK receptor, TweakR). This receptor is naturally engaged by its ligand TWEAK (TNFRSF12A), which activates various cellular responses. By binding to TweakR, Enavatuzumab inhibits tumor proliferation through direct receptor signaling and promotes antibody-dependent cell-mediated cytotoxicity (ADCC). This antibody has demonstrated efficacy in recruiting and activating myeloid effector cells to eradicate tumor cells. Enavatuzumab has shown to inhibit the growth of a range of human TweakR-positive cancer cell lines and xenografts both in vitro and in vivo, marking it as a potent therapeutic agent in cancer research and treatment.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
